TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 355-360

  Kim, Jong Gwang ^a   Sohn, Sang Kyun ^a   Chae, Yee Soo ^a   Song, Hong Suk ^b   Kwon, Ki Young ^b   Do, Young Rok ^b   Kim, Min Kyoung ^c   Lee, Kyung Hee ^c   Hyun, Myung Soo ^c   Lee, Won Sik ^d   Sohn, Chang Hak ^e   Jung, Joo Seop ^f   Kim, Gab Chul ^a   Chung, Ho Young ^a   Yu, Wansik ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Keimyung University   (South Korea)

^c Young Nam University Hospital   (South Korea)

^d Daegu Fatima Hospital   (South Korea)

^e Inje University   (South Korea)

^f Pusan National University Hospital   (South Korea)

Author keywords

Chemotherapy; Gastric cancer; Polymorphism; TP53

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 9; CISPLATIN; PACLITAXEL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CODON; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349111011     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0879-3     Document Type: Article

References (27)

1. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Ransch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 (Pubitemid 23182046)
2. S Pyrhonen T Kuitunen M Kouri 1995 A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer Br J Cancer 71 587 591
3. B Glimelius K Hoffmann U Haglund O Nyron PO Sjoden 1994 Initial or delayed chemotherapy with best supportive in advanced gastric cancer Ann Oncol 5 189 190 (Pubitemid 24062577)
4. NK Kim YS Park DS Heo C Suh SY Kim KC Park YK Kang DB Shin HT Kim HJ Kim WK Kang CI Suh YJ Bang 1993 A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813 3818 (Pubitemid 23172955)
5. U Vanhoefer T Wagner M Lutz E Van Cutsem B Nordlinger S Reuse B Baron H Wilke J Wils 2001 Randomized phase II study of weekly 24-h infusion of high dose 5-FU ± folinic acid (HD-FU ± FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953 Eur J Cancer 37 27
6. AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani R Morant MM Borner R Hermann H Honegger F Cavalli P Alberto M Castighine A Goldhirsch 2000 Docetaxel (taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma Ann Oncol 11 301 306 (Pubitemid 30214667)
7. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito Y Sakata I Hyodo 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323 (Pubitemid 29022409)
8. JA Ajani J Fairweather P Dumas YZ Patt R Pazdur PF Mansfield 1998 Phase II study of taxol in patients with advanced gastric carcinoma Cancer J Sci Am 4 269 274
9. C Bokemeyer CS Lampe MR Clemens JT Hartmann D Quietzsch L Forkmann C Kollmannsberger L Kanz 1997 A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer Anticancer Drugs 8 396 399 (Pubitemid 27204960)
10. C Kollmannsberger D Quietzsch C Haag T Lingenfelser M Schroeder JT Hartmann W Baronius V Hempd M Uemens L Kanz C Bokemeyer 2000 A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer Br J Cancer 83 458 462 (Pubitemid 30487857)
11. MK Kim KH Lee MS Hyun YR Do HS Song WS Lee KU Park JH Baek JG Kim 2005 A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer Cancer Res Treat 37 349 353
12. JG Kim SK Sohn HS Song KY Kwon YR Do KH Lee MS Hyun HM Ryoo SH Bae KU Park JH Baek WS Lee JS Chung GJ Cho CH Sohn JS Jang HY Chung W Yu 2007 Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer Cancer Chemother Pharmacol 60 863 869 (Pubitemid 47389392)
13. PA Ellis IE Smith K McCarthy S Detre J Salter M Dowsett 1997 Preoperative chemotherapy induces apoptosis in early breast cancer Lancet 349 849 (Pubitemid 27129217)
14. JF Kerr CM Winterford BV Harmon 1994 Apoptosis. Its significance in cancer and cancer therapy Cancer 73 2013 2026 (Pubitemid 24107952)
15. M Thomas A Kalita S Labrecque D Pim L Bank G Matlashewski 1999 Two polymorphic variants of wild-type p53 differ biochemically and biologically Mol Cell Biol 19 1092 1100 (Pubitemid 29046852)
16. P Dumont JL Leu III Della Pietra AC DL George M Murphy 2003 The codon 72 polymorphic variants of p53 have markedly different apoptosis potential Nat Genet 33 357 365 (Pubitemid 36278852)
17. P Rajaraman SS Wang N Rothman MM Brown PM Black HA Fine JS Loeffler RG Selker WR Shapiro SJ Chanock PD Inskip 2007 polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults Cancer Epidemiol Biomarkers Prev 16 1655 1661 (Pubitemid 47294834)
18. Y Xu L Yao T Ouyang J Li T Wang Z Fan B Lin Y Lu Y Xie 2005 p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer Clin Cancer Res 11 7328 7333 (Pubitemid 41507691)
19. N Ohmiya A Taguchi N Mabuchi A Itoh Y Hirooka Y Niwa H Goto 2006 MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis J Clin Oncol 24 4434 4440 (Pubitemid 46630981)
20. ZW Zhang NJ Laurence A Hollowood P Newcomb M Moorghen J Gupta R Feakins MJG Farthing D Alderson J Holly 2004 Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma Clin Cancer Res 10 131 135 (Pubitemid 38114171)
21. YC Wang HS Lee SK Chen YY Chang CY Chen 1999 Prognostic significance of p53 codon 72 polymorphism in lung carcinoma Eur J Cancer 35 226 230
22. P Therasse SG Arbuck EA Eisenhauer J Wanders JS Kaplan L Rubinstein J Verweij M Van Glabbeke AT Van Qosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
23. D Pim L Banks 2004 p53 Polymorphic variants at codon 72 exert different effects on cell cycle progression Int J Cancer 108 196 199 (Pubitemid 37541770)
24. A Sullivan N Syed M Gasco D Bergamaschi G Trigiante M Attard L Hiller PJ Farrell P Smith X Lu T Crook 2004 Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo Oncogene 23 3328 3337 (Pubitemid 38669822)
25. T Toyama Z Zhang M Nishio M Hamaguchi N Kondo H Iwase H Iwata S Takahashi H Yamashita Y Fujii 2007 Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients Breast Cancer Res 9 R34
26. Y Wang P Kringen GB Kristensen R Holm MMO Baekelandt M Oliver H Skomedal P Hainaut CG Trope VM Abeler JM Nesland AL Borresen-Dale A Helland 2004 Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advance ovarian carcinoma Hum Mutat 24 21 34 (Pubitemid 38859221)
27. AM Santos H Sousa C Portela D Pereira D Pinto R Catarino C Rodrigues AP Araujo C Lopes R Medeiros 2006 TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer Biochem Biophys Res Commun 340 256 262 (Pubitemid 41827674)